ANTONARELLI, GABRIELE
ANTONARELLI, GABRIELE
Universita' degli Studi di MILANO
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
2026 C. Valenza, Y. Zheng, M. Milano, D. Trapani, E. Giordano, L. Guidi, P.P.M. Berton Giachetti, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, F. Conforti, E. Pagan, V. Bagnardi, G.J. Kirkner, C. Sangalli, K.E. Dibble, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study
2026 C. Valenza, J.D. Etessami, M. Milano, N. Papadopoulos, M. Alvino, G. Antonarelli, N. Bianco, C. Sangalli, D. Trapani, G. Pravettoni, E. Omodeo Salè, R. Passerini, M. Colleoni, E. Munzone, G. Curigliano
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
2025 R. Asnaghi, G. Antonarelli, E. Battaiotto, G. Castellano, L. Guidi, D. Izzo, P. Zagami, D. Trapani, G. Curigliano
Redefining clinical trial strategic design to support drug approval in medical oncology
2025 G. Antonarelli, J.M. Pérez-García, M. Gion, H. Rugo, P. Schmid, A. Bardia, S. Hurvitz, N. Harbeck, S.M. Tolaney, G. Curigliano, A. Llombart-Cussac, J. Cortés
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer
2025 G. Antonarelli, M. Milano, C. Andreon, S. Gandini, G. Pellizzari, D. Trapani, S. Dellapasqua, A. Marra, P. Zagami, C. Valenza, M. Colleoni, E. Munzone, G. Curigliano
From Dose-Finding to Dose-Optimization in Early-Phase oncology clinical trials
2025 E. Almuradova, D. Izzo, S. Gandini, A. Gaeta, E. Giordano, C. Valenza, G. Antonarelli, D. Trapani, G. Curigliano
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
2024 C. Valenza, D. Trapani, P. Zagami, G. Antonarelli, L. Boscolo Bielo, E. Nicolò, J.M. Ribeiro, L. Guidi, C. Reduzzi, M. Spotti, L. Adamoli, J. Cortès, B. Pistilli, S.M. Tolaney, N. Ueno, R.M. Layman, M. Cristofanilli, L.A. Carey, E. Munzone, C. Criscitiello, F. Lynce, W.A. Woodward, G. Curigliano
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Beyond PD(L)-1 blockade in microsatellite-instable cancers: current landscape of immune co-inhibitory receptor targeting
2024 E. Crimini, L. Boscolo Bielo, P.P.M. Berton Giachetti, G. Pellizzari, G. Antonarelli, B. Taurelli Salimbeni, M. Repetto, C. Belli, G. Curigliano
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers
2023 P. Zagami, A. Comandone, M. Fiore, G. Giulio Baldi, G. Grignani, B. Vincenzi, A. Gronchi, G. Antonarelli, A. Boglione, E. Pennacchioli, G. Curigliano, F. Conforti, T.M. De Pas
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
2023 G. Antonarelli, V. Pieri, F.M. Porta, N. Fusco, G. Finocchiaro, G. Curigliano, C. Criscitiello
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
Tumor infiltrating lymphocytes across breast cancer subtypes: current issues for biomarker assessment
2023 C. Valenza, B. Taurelli Salimbeni, C. Santoro, D. Trapani, G. Antonarelli, G. Curigliano
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
2022 C. Corti, G. Antonarelli, F. Scotte, J.P. Spano, J. Barriere, J.M. Michot, F. Andre, G. Curigliano
Harmonizing PD-L1 testing in metastatic triple negative breast cancer
2022 F. Giugliano, G. Antonarelli, P. Tarantino, J. Cortes, H.S. Rugo, G. Curigliano
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
2022 C. Corti, G. Antonarelli, C. Valenza, E. Nicolò, H. Rugo, J. Cortés, N. Harbeck, L.A. Carey, C. Criscitiello, G. Curigliano
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development
2022 P. Tarantino, G. Antonarelli, L. Ascione, G. Curigliano